Anzeige
Meldung des Tages: Der nächste Lithium-Runner? EMP startet entscheidende Engineering-Phase

Zymeworks News

Aktie
WKN:  A3DSSN ISIN:  US98985Y1082 US-Symbol:  ZYME Branche:  Biotechnologie Land:  USA
20,20 €
+0,2 €
+1,00%
13:13:43 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,57 Mrd. €
Streubesitz
-
KGV
-9,04
Index-Zuordnung
-

Zymeworks News

02.03.26 - GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Zymeworks to receive $250 million under a royalty-​backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully ...
27.01.26 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare ...
12.01.26 - GlobeNewswire
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood ...
12.01.26 - GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Positive Phase 3 HERIZON-​GEA-01 results for Ziihera ® (zanidatamab-​hrii) in first-​line HER2-positive (HER2+)  gastroesophageal adenocarcinoma ( GEA) presented at ASCO GI ...
06.01.26 - GlobeNewswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Positive results from Phase 3 HERIZON-​GEA-01 results support Ziihera as the HER2-targeted agent-​of-choice in HER2+ first-​line metastatic GEA and Ziihera plus chemotherapy to ...
18.11.25 - GlobeNewswire
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare ...
18.11.25 - GlobeNewswire
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders Strategic initiative follows positive topline results ...
17.11.25 - GlobeNewswire
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful ...
23.10.25 - GlobeNewswire
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-...
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
13.10.25 - GlobeNewswire
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-​NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, ...
09.10.25 - GlobeNewswire
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
02.09.25 - GlobeNewswire
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
19.08.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
11.08.25 - GlobeNewswire
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
28.07.25 - GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Second antibody-​drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-...
17.07.25 - GlobeNewswire
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August
30.05.25 - GlobeNewswire
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-...
22.05.25 - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® ...

Newssuche

Videos

newspaper
10.03.26 -12,09%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »